Treatment for Acute Deep Vein Thrombosis (DVT)

Initial Management

The American College of Chest Physicians recommends direct oral anticoagulants (DOACs) such as apixaban, dabigatran, edoxaban, or rivaroxaban over vitamin K antagonists (VKAs) as first-line treatment for patients with acute DVT 1
For patients with acute DVT treated with VKA therapy, initial treatment with parenteral anticoagulation (LMWH, fondaparinux, IV UFH, or SC UFH) is recommended, with low-molecular-weight heparin (LMWH) or fondaparinux preferred over intravenous unfractionated heparin (IV UFH) and over subcutaneous UFH 1, 2
For patients with acute DVT who are candidates for VKA therapy, early initiation of VKA (same day as parenteral therapy) is recommended with continuation of parenteral anticoagulation for a minimum of 5 days and until the INR is ≥2.0 for at least 24 hours 1, 2
For patients with DVT in the setting of cancer, oral factor Xa inhibitors (apixaban, edoxaban, rivaroxaban) are recommended over LMWH for initial and treatment phases 1

For patients with acute DVT of the leg whose home circumstances are adequate, initial treatment at home is recommended over treatment in hospital, with early ambulation suggested over initial bed rest 1, 4
Home treatment is conditional on well-maintained living conditions, strong support from family or friends, phone access, and ability to quickly return to hospital if deterioration occurs 4

A minimum 3-month treatment phase of anticoagulation is recommended for patients with objectively confirmed DVT 1
For patients with DVT secondary to a major transient risk factor, extended anticoagulation beyond 3 months is not recommended 1
For patients with unprovoked DVT or DVT provoked by persistent risk factors, extended anticoagulation with a DOAC is recommended 1
For patients with DVT and active cancer who do not have high bleeding risk, extended anticoagulant therapy (no scheduled stop date) is recommended 1

For patients with isolated distal DVT without severe symptoms or risk factors for extension, serial imaging of deep veins for 2 weeks is suggested over initial anticoagulation 2, 4
For patients with acute proximal DVT, anticoagulant therapy alone is generally suggested over catheter-directed thrombolysis 4
For patients with acute DVT, an inferior vena cava (IVC) filter is not recommended in addition to anticoagulants, but is recommended for patients with acute proximal DVT and contraindication to anticoagulation 4

For patients treated with VKA, a therapeutic INR range of 2.0-3.0 (target INR 2.5) is recommended 1
When using LMWH, once-daily administration is suggested over twice-daily administration when using the same total daily dose 4

When transitioning from parenteral anticoagulation to VKA, continue parenteral therapy until the INR is therapeutic (≥2.0) for at least 24 hours 2, 4